REPL logo

REPL
Replimune Group Inc

3,338
Mkt Cap
$576.36M
Volume
159,839.00
52W High
$13.24
52W Low
$2.68
PE Ratio
-1.95
REPL Fundamentals
Price
$6.93
Prev Close
$6.98
Open
$6.86
50D MA
$7.58
Beta
0.80
Avg. Volume
1.27M
EPS (Annual)
-$3.07
P/B
2.64
Rev/Employee
$0.00
$377.86
Loading...
Loading...
News
all
press releases
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.
Zacks·7d ago
News Placeholder
More News
News Placeholder
Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL
Boxer Capital Management LLC decreased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 52.5% during the 3rd quarter, according to the company in its most recent filing...
MarketBeat·9d ago
News Placeholder
Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL
Braidwell LP raised its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 550.3% in the third quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·9d ago
News Placeholder
Replimune Group (NASDAQ:REPL) Stock Price Down 8% - Here's What Happened
Replimune Group (NASDAQ:REPL) Stock Price Down 8% - Should You Sell...
MarketBeat·11d ago
News Placeholder
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
MLYS shares rise after the FDA accepts NDA for lorundrostat to treat hypertension. A decision from the regulatory body is due on Dec. 22, 2026.
Zacks·13d ago
News Placeholder
JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
J&J gains EU approval to expand Akeega use to treat patients with BRCA-mutated metastatic hormone-sensitive prostate cancer.
Zacks·14d ago
News Placeholder
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.
Zacks·14d ago
News Placeholder
Replimune Group (NASDAQ:REPL) Trading 11.1% Higher - Here's Why
Replimune Group (NASDAQ:REPL) Trading 11.1% Higher - Here's What Happened...
MarketBeat·18d ago
News Placeholder
Mirum Completes Enrollment & Screening in Liver Disease Studies
MIRM completes enrollment in phase III AZURE-1 and screening in AZURE-4 for brelovitug in HDV, with top-line data expected in the second half of 2026.
Zacks·18d ago
News Placeholder
Bayer Advances Roundup Settlement With Missouri Court Approval
BAYRY wins preliminary court approval for a proposed Roundup class settlement, a key step in managing long-running glyphosate litigation and future liabilities.
Zacks·19d ago
<
1
2
...
>

Latest REPL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.